268 related articles for article (PubMed ID: 35566014)
21. Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies.
Kumar Verma A; Kumar V; Singh S; Goswami BC; Camps I; Sekar A; Yoon S; Lee KW
Biomed Pharmacother; 2021 May; 137():111356. PubMed ID: 33561649
[TBL] [Abstract][Full Text] [Related]
22. Some Flavolignans as Potent Sars-Cov-2 Inhibitors
Cetin A
Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852
[TBL] [Abstract][Full Text] [Related]
23. CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy.
Rabie AM
Mol Divers; 2021 Aug; 25(3):1839-1854. PubMed ID: 33389560
[TBL] [Abstract][Full Text] [Related]
24. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
25. In Silico Screening of Some Active Phytochemicals to Identify Promising Inhibitors Against SARS-CoV-2 Targets.
Alagarsamy V; Solomon VR; Murugesan S; Sundar PS; Muzaffar-Ur-Rehman MD; Chandu A; Aishwarya AD; Narendhar B; Sulthana MT; Ravikumar V
Curr Drug Discov Technol; 2023 Oct; ():. PubMed ID: 37861016
[TBL] [Abstract][Full Text] [Related]
26. The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis.
Marciniec K; Beberok A; Boryczka S; Wrześniok D
Pharmacol Rep; 2021 Dec; 73(6):1765-1780. PubMed ID: 34052981
[TBL] [Abstract][Full Text] [Related]
27. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2
Singh S; Sk MF; Sonawane A; Kar P; Sadhukhan S
J Biomol Struct Dyn; 2021 Oct; 39(16):6249-6264. PubMed ID: 32720577
[TBL] [Abstract][Full Text] [Related]
28. Exploration of potent antiviral phytomedicines from Lauraceae family plants against SARS-CoV-2 RNA-dependent RNA polymerase.
Rabaan AA; Halwani MA; Aljeldah M; Al Shammari BR; Garout M; Aldali J; Alawfi A; Alshengeti A; Alsulaiman AM; Alsayyah A
J Biomol Struct Dyn; 2023; 41(24):15085-15105. PubMed ID: 36883874
[TBL] [Abstract][Full Text] [Related]
29. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
[TBL] [Abstract][Full Text] [Related]
30. A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease.
Rieder AS; Deniz BF; Netto CA; Wyse ATS
Neurotox Res; 2022 Oct; 40(5):1553-1569. PubMed ID: 35917086
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the inhibitory potential of bioactive compounds against SARS-CoV-2 by in silico approach.
Rani JMS; Akkarshana P; Neelaveni V; Mohan S; Rekha PD; Rao RM; Muthulakshmi L
J Mol Model; 2024 Feb; 30(3):60. PubMed ID: 38321299
[TBL] [Abstract][Full Text] [Related]
32. Mechanistic Aspects of Medicinal Plants and Secondary Metabolites against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Malekmohammad K; Rafieian-Kopaei M
Curr Pharm Des; 2021; 27(38):3996-4007. PubMed ID: 34225607
[TBL] [Abstract][Full Text] [Related]
33. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
34. Virtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV.
Patel A; Rajendran M; Shah A; Patel H; Pakala SB; Karyala P
J Biomol Struct Dyn; 2022 Jul; 40(11):5138-5146. PubMed ID: 33397223
[TBL] [Abstract][Full Text] [Related]
35. Arjunetin as a promising drug candidate against SARS-CoV-2: molecular dynamics simulation studies.
Arumugam GS; Sen A; Dash SS; Mitra K; Doble M; Rajaraman G; Gummadi SN
J Biomol Struct Dyn; 2022; 40(22):12358-12379. PubMed ID: 34533107
[TBL] [Abstract][Full Text] [Related]
36. Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir.
Banerjee A; Kanwar M; Maiti S
Drug Res (Stuttg); 2021 Oct; 71(8):462-472. PubMed ID: 34517419
[TBL] [Abstract][Full Text] [Related]
37. Quinic and Digallic acids from
Benguechoua MI; Benarous K; Benahmed Z; Boukhalkhal S; Silva AMS; Yousfi M
Curr Comput Aided Drug Des; 2022; 18(4):307-317. PubMed ID: 35713136
[TBL] [Abstract][Full Text] [Related]
38. Plant-derived active compounds as a potential nucleocapsid protein inhibitor of SARS-CoV-2: an
Kashyap D; Roy R; Kar P; Jha HC
J Biomol Struct Dyn; 2023 Jul; 41(10):4770-4785. PubMed ID: 35532092
[TBL] [Abstract][Full Text] [Related]
39. Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein.
Manjunathan R; Periyaswami V; Mitra K; Rosita AS; Pandya M; Selvaraj J; Ravi L; Devarajan N; Doble M
BMC Bioinformatics; 2022 May; 23(1):180. PubMed ID: 35578172
[TBL] [Abstract][Full Text] [Related]
40. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
